Shots:

• Wuxi Biologic to take over operations of Bayer’s manufacturing plants in Leverkusen- Germany and purchase its associated equipment in combination with a long-term lease contract for the building
• As per the manufacturing agreement to be negotiated- Wuxi operated plant shall serve as a backup site for manufacturing Kovaltry- an antihemophilic factor (recombinant) while Bayer’s facility in California- US will remain the major site for manufacturing and filing of it
• Kovaltry is used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in patients with hemophilia A and controls bleeding in hemophilic patients

Click here ­to­ read full press release/ article | Ref: Bayer | Image: The Pharma Letter